ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023
Prostate-Specific Antigen Level at the Time of Salvage Therapy After Radical Prostatectomy for Prostate Cancer and the Risk of Death.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Stereotactic body radiation therapy after radical prostatectomy: current status and future directions.World journal of urology · 2023Pooled it
- Multicenter ProKnow-based plan evaluation of postprostatectomy salvage radiotherapy patients using SPPORT and RADICALS-HD trial-defined dose constraints.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
- Early detection and localization of recurrent prostate cancer using [Formula: see text]F-DCFPyL PET/CT in patients with low and ultra-low PSA levels.EJNMMI research · 2026Article
- Racial Differences in Secondary Treatment Pathways and Survival in Localized Prostate Cancer.JAMA network open · 2026Article
- Acute toxicity and quality of life in postoperative prostate cancer patients treated with ultra-hypofractionated pelvic radiation therapy.Radiation oncology journal · 2026Article
- Prognosis of patients with early salvage radiotherapy and low persisting or increasing PSA levels after radical prostatectomy for prostate cancer. A retrospective comparative analysis.Clinical and translational radiation oncology · 2026Article
- Salvage stereotactic body radiotherapy for post-prostatectomy recurrence: are we almost there?Journal of radiation research · 2026Review
- Real world comparison of adjuvant vs. salvage radiation therapy on cancer-control outcomes after radical prostatectomy.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
- Safety and functional outcomes of modified maximum peri-prostatic anatomy preserving-robotic assisted laparoscopic radical prostatectomy base on Da Vinci robot.Journal of robotic surgery · 2025Article
- Anatomical distribution of disease in pN1 prostate cancer with BCR post-RP: A PSMA-PET/CT-based analysis.BJUI compass · 2025Article
- Influence of PSA level at salvage radiotherapy on metastasis-free survival following radical prostatectomy.World journal of urology · 2025Article
- Current status and perspectives on the use of androgen receptor pathway inhibitors in the salvage radiotherapy setting.Prostate cancer and prostatic diseases · 2025Review
- Understanding the Impact of Salvage Radiation on the Long-Term Natural History of Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.Cancer medicine · 2025Article
- PSMA PET/CT findings in high-risk biochemical recurrence after local treatment of prostate cancer.BJUI compass · 2025Article
- Shaping Clinical Policy for Salvage Radiotherapy After Radical Prostatectomy in Prostate Cancer: Bridging the Gap Between Clinical Trials and Daily Practice.Cancer medicine · 2024Article
- Article
- Article
- Prognostic significance of a negative PSMA PET/CT in biochemical recurrence of prostate cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Observational
- Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification.Prostate cancer and prostatic diseases · 2024Review
- European association of urology biochemical recurrence risk stratification in the context of post-prostatectomy salvage therapy.Translational andrology and urology · 2024Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
10 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBoth the performance characteristics of prostate-specific membrane antigen positron emission tomography and insurance approval improves with increasing prostate-specific antigen (PSA) level causing some physicians to delay post-radical prostatectomy salvage radiation therapy (sRT) after PSA failure. Yet, it is unknown for men with at most one high-risk factor (ie, pT3/4 or prostatectomy [p] Gleason score 8-10) whether a PSA level exists above which initiating sRT is associated with increased all-cause mortality (ACM)-risk and was investigated.
methodsUsing a multinational database of 25,551 patients with pT2-4N0 or NXM0 prostate cancer, multivariable Cox regression analysis evaluated whether an association with a significant increase in ACM-risk existed when sRT was delivered above a prespecified PSA level beginning at 0.10 ng/mL and in 0.05 increments up to 0.50 ng/mL versus at or below that level. The model was adjusted for age at and year of radical prostatectomy, established prostate cancer prognostic factors, institution, and the time-dependent use of androgen deprivation therapy.
resultsAfter a median follow-up of 6.00 years, patients who received sRT at a PSA level >0.25 ng/mL had a significantly higher ACM-risk (AHR, 1.49; 95% CI, 1.11 to 2.00;
conclusionAmong patients with at most one high-risk factor, initiating sRT above a PSA level of 0.25 ng/mL was associated with increased ACM-risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.